ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ascendis Pharma A/S statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Income (trailing twelve months)
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Revenue | €720.13M | €447.40M |
| Gross Profit | €625.22M | €1.08B |
| Operating Income | -€136.27M | -€68.03M |
| Pretax Income | -€212.65M | -€49.18M |
| Net Income | -€228.03M | -€6.53M |
| EBITDA | -€136.27M | -€48.04M |
| EPS (Diluted) | -3.76 EUR | -0.61 EUR |
Margins
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Gross Margin | 86.8% | 42.8% |
| Operating Margin | -18.9% | -33.2% |
| Pretax Margin | -29.5% | -36.6% |
| Profit Margin | -31.7% | -31.7% |
| EBITDA Margin | -18.9% | -28.6% |
Returns
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Return on Assets (ROA) | -18.4% | -5.10% |
| Return on Capital Employed (ROCE) | -58.4% | -26.9% |
Growth
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 98.0% | 1.99% |
| Revenue Growth (3Y CAGR) | 141.4% | 13.5% |
| Revenue Growth (5Y CAGR) | 153.0% | 11.0% |
Balance sheet
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €616.04M | €291.68M |
| Total Debt | €814.65M | €496.91M |
| Net Cash (Debt) | -€198.60M | €87.54M |
| Net Cash Per Share | -3.20 EUR | 1.09 EUR |
| Working Capital | €39.59M | €121.78M |
Financial position
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Current Ratio | 1.04 | 2.81 |
| Quick Ratio | 0.71 | 1.23 |
| Interest Coverage | -0.66 | -0.90 |
Cash flow (trailing twelve months)
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Operating Cash Flow | €53.90M | -€35.31M |
Efficiency
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Asset Turnover | 0.58 | 0.32 |
| Inventory Turnover | 0.32 | 1.33 |
| Revenue Per Employee | €819.26K | €420.86K |
| Profits Per Employee | -€259.42K | -€247.02K |
| Employee Count | 879 | 378 |
Shares
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Shares Outstanding | 61,977,400 | 105,361,000 |
| Shares Change (YoY) | 4.69% | 6.28% |
| Float | 61,462,900 | 78,574,400 |
| Shares Held by Insiders | 0.83% | 9.05% |
Taxes
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Income Tax | €15.38M | €1.53M |
Scores
| Measure | Ascendis Pharma A/S | Industry median |
|---|---|---|
| Piotroski F-Score | 5 | 5 |
Calculated by StockData from Ascendis Pharma A/S's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.